Orteronel Leaves Hole In Millennium/Takeda Pipeline
This article was originally published in Pharmaceutical Approvals Monthly
The non-steroidal androgen synthesis inhibitor failed to show a survival benefit in chemotherapy-naïve prostate cancer patients after also failing in post-chemo patients in 2013. With Takeda ending development of the Phase III candidate, its Millennium cancer pipeline is reduced to a pair of Phase III candidates.
You may also be interested in...
In an interview with “The Pink Sheet” at Elsevier’s PSA 2013 conference, Takeda’s R&D chief spoke of progress in building a global vaccine business and of the key late-stage assets that will carry the company into the next decade.
Takeda’s Millennium oncology unit will absorb Intellikine’s programs in a deal paying $190 million upfront to buy out the privately held biotech.
Five-point plan that calls for FDA to change definition of ‘labeling’ and ‘substantial evidence’ may offer hints as to what the next iteration of 21st Century Cures legislation will offer.